Online inquiry

IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1544MR)

This product GTTS-WQ1544MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Duchenne muscular dystrophy (DMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1544MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14847MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ8308MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ14530MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ11034MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ4227MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ14031MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ8063MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ14150MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW